Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss, Gregory L
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. [electronic resource] - Epilepsia 04 2018 - 866-876 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1528-1167
10.1111/epi.14044 doi
Anticonvulsants--administration & dosage
Dizziness--chemically induced
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Epilepsies, Partial--diagnosis
Female
Follow-Up Studies
Headache--chemically induced
Humans
Nitriles
Pyridones--administration & dosage
Seizures--diagnosis
Time Factors
Treatment Outcome
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307. [electronic resource] - Epilepsia 04 2018 - 866-876 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1528-1167
10.1111/epi.14044 doi
Anticonvulsants--administration & dosage
Dizziness--chemically induced
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Epilepsies, Partial--diagnosis
Female
Follow-Up Studies
Headache--chemically induced
Humans
Nitriles
Pyridones--administration & dosage
Seizures--diagnosis
Time Factors
Treatment Outcome